

# Remington's Pharmaceutical Sciences

EDITED BY THE EDITORIAL BOARD OF THE AMERICAN PHARMACEUTICAL ASSOCIATION

Eighteenth Edition

Entered according to Act of Congress, in the year 1885 by Joseph P Remington,  
in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by Joseph P Remington Estate

Copyright 1948, 1951, by The Philadelphia College of Pharmacy and Science

Copyright © 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, by The Philadelphia College of  
Pharmacy and Science

*All Rights Reserved*

Library of Congress Catalog Card No. 60-53334

ISBN 0-912734-04-3

*The use of structural formulas from USAN and the USP Dictionary of Drug Names is by  
permission of The USP Convention. The Convention is not responsible for any inaccuracy  
contained herein.*

*NOTICE—This text is not intended to represent, nor shall it be interpreted to be, the equivalent  
of or a substitute for the official United States Pharmacopeia (USP) and/or the National  
Formulary (NF). In the event of any difference or discrepancy between the current official  
USP or NF standards of strength, quality, purity, packaging and labeling for drugs and  
representations of them herein, the context and effect of the official compendia shall  
prevail.*

*Printed in the United States of America by the Mack Printing Company, Easton, Pennsylvania*

# Table of Contents

<b>Part 1 Orientation</b>		44 Cholinomimetic Drugs .....	889
1 Scope .....	3	45 Adrenergic and Adrenergic Neuron Blocking Drugs .....	898
2 Evolution of Pharmacy .....	8	46 Antimuscarinic and Antispasmodic Drugs .....	907
3 Ethics .....	20	47 Skeletal Muscle Relaxants .....	916
4 The Practice of Community Pharmacy .....	28	48 Diuretic Drugs .....	929
5 Opportunities for Pharmacists in the Pharmaceuti- cal Industry .....	33	49 Uterine and Antimigraine Drugs .....	943
6 Pharmacists in Government .....	38	50 Hormones .....	948
7 Drug Information .....	49	51 Vitamins and Other Nutrients .....	1002
8 Research .....	60	52 Enzymes .....	1035
<b>Part 2 Pharmaceutics</b>		53 General Anesthetics .....	1039
9 Metrology and Calculation .....	69	54 Local Anesthetics .....	1048
10 Statistics .....	104	55 Sedatives and Hypnotics .....	1057
11 Computer Science .....	138	56 Antiepileptics .....	1072
12 Calculus .....	145	57 Psychopharmacologic Agents .....	1082
13 Molecular Structure, Properties and States of Matter .....	158	58 Analgesics and Antipyretics .....	1097
14 Complex Formation .....	182	59 Histamine and Antihistamines .....	1123
15 Thermodynamics .....	197	60 Central Nervous System Stimulants .....	1132
16 Solutions and Phase Equilibria .....	207	61 Antineoplastic and Immunosuppressive Drugs ...	1138
17 Ionic Solutions and Electrolytic Equilibria .....	228	62 Antimicrobial Drugs .....	1163
18 Reaction Kinetics .....	247	63 Parasitocides .....	1242
19 Disperse Systems .....	257	64 Pesticides .....	1249
20 Rheology .....	310	65 Diagnostic Drugs .....	1272
<b>Part 3 Pharmaceutical Chemistry</b>		66 Pharmaceutical Necessities .....	1286
21 Inorganic Pharmaceutical Chemistry .....	329	67 Adverse Drug Reactions .....	1330
22 Organic Pharmaceutical Chemistry .....	356	68 Pharmacogenetics .....	1344
23 Natural Products .....	380	69 Pharmacological Aspects of Drug Abuse .....	1349
24 Drug Nomenclature—United States Adopted Names .....	412	70 Introduction of New Drugs .....	1365
25 Structure-Activity Relationship and Drug Design .....	422	<b>Part 7 Biological Products</b>	
<b>Part 4 Testing and Analysis</b>		71 Principles of Immunology .....	1379
26 Analysis of Medicinals .....	435	72 Immunizing Agents and Diagnostic Skin Antigens .....	1389
27 Biological Testing .....	484	73 Allergenic Extracts .....	1405
28 Clinical Analysis .....	495	74 Biotechnology and Drugs .....	1416
29 Chromatography .....	529	<b>Part 8 Pharmaceutical Preparations and Their Manufacture</b>	
30 Instrumental Methods of Analysis .....	555	75 Preformulation .....	1435
31 Dissolution .....	589	76 Bioavailability and Bioequivalency Testing .....	1451
<b>Part 5 Radioisotopes in Pharmacy and Medicine</b>		77 Separation .....	1459
32 Fundamentals of Radioisotopes .....	605	78 Sterilization .....	1470
33 Medical Applications of Radioisotopes .....	624	79 Tonicity, Osmoticity, Osmolality and Osmolarity .	1481
<b>Part 6 Pharmaceutical and Medicinal Agents</b>		80 Plastic Packaging Materials .....	1499
34 Diseases: Manifestations and Patho- physiology .....	655	81 Stability of Pharmaceutical Products .....	1504
35 Drug Absorption, Action and Disposition .....	697	82 Quality Assurance and Control .....	1513
36 Basic Pharmacokinetics .....	725	83 Solutions, Emulsions, Suspensions and Extractives .....	1519
37 Clinical Pharmacokinetics .....	746	84 Parenteral Preparations .....	1545
38 Topical Drugs .....	757	85 Intravenous Admixtures .....	1570
39 Gastrointestinal Drugs .....	774	86 Ophthalmic Preparations .....	1581
40 Blood, Fluids, Electrolytes and Hematologic Drugs .....	800	87 Medicated Applications .....	1596
41 Cardiovascular Drugs .....	831	88 Powders .....	1615
42 Respiratory Drugs .....	860	89 Oral Solid Dosage Forms .....	1633
43 Sympathomimetic Drugs .....	870	90 Coating of Pharmaceutical Dosage Forms .....	1666
		91 Sustained-Release Drug Delivery Systems .....	1676
		92 Aerosols .....	1694
		<b>Part 9 Pharmaceutical Practice</b>	
		93 Ambulatory Patient Care .....	1715
		94 Institutional Patient Care .....	1737
		95 Long-Term Care Facilities .....	1758
		96 The Pharmacist and Public Health .....	1773



## CHAPTER 75

# Preformulation

### Louis J Ravin, PhD

Department of Pharmaceutics  
Research & Development  
Smith Kline & French Laboratories  
King of Prussia, PA 19406

### Galen W Radebaugh, PhD

Director of Pharmaceutics  
Parke-Davis Pharmaceutical Research Division  
Warner-Lambert Co  
Morris Plains, NJ 07950

The attention presently being given to multisource pharmaceutical products regarding their equivalency places much emphasis on the formulation of these products. In some instances, the bioavailability of a drug formulation represents a quality parameter of enormous proportion. It is a matter of record that with certain drugs, depending on the formulation, the rate at which the drug substance becomes available can vary significantly from very high to none at all. As a result, the effectiveness of these formulations will range dramatically from that expected to no effect. Unfortunately, most examples are less dramatic and fall somewhere in between. The difference in the bioavailability of these drug products is less readily discernible, but nonetheless real. This has led to a great deal of confusion and information which, though understood by the scientist, is unclear and jumbled to the practitioner. That information which is available also has been interpreted differently by different individuals or groups, depending very often on the motivation, viewpoint and attitude of the interpreter.

Drug products indeed do vary in their bioavailability characteristics and this variation, in most instances, is related directly to formulation considerations. To optimize the performance of drug products, it is necessary to have a complete understanding of the physical-chemical properties of drug substances prior to formulating them into drug products. The development of an optimum formulation is not an easy task, and many factors readily influence formulation properties. Drug substances rarely are administered as chemical entities, but almost always are given in some kind of formulation. These may vary from a simple solution to a very complex drug delivery system. The complexity usually is not intentional, but rather is determined by the properties that are expected from or built into the dosage form and by the resulting composition that is required to achieve these qualities.

The high degree of uniformity, physiological availability and therapeutic quality expected of modern medicinal products usually are the results of considerable effort and expertise on the part of the formulating pharmacist. These qualities are attained by careful selection and control of the quality of the various ingredients employed, appropriate manufacturing according to well-defined processes and, most importantly, adequate consideration of the many variables that may influence the composition, stability and utility of the product. In dealing with the formulation of new products it has become necessary to apply the best research methods and tools in order to develop, produce and control the potent, stable and effective dosage forms which make up our modern medical armamentarium.

The pharmaceutical formulator has need for specialized

areas of science in order to acquire scientific information about the drug substance which is necessary to develop an optimum dosage form. The pharmaceutical industry is in an era in which one can no longer rely on past experience to formulate. A thorough understanding of the physical and chemical properties as well as the pharmacokinetic and biopharmaceutical behavior of each drug substance being developed is necessary. In short, as much information as possible must be acquired about the drug substance very early in its development. This requires an interdisciplinary approach at the preformulation stage of development. Fig 75-1 schematically indicates that the development of any drug product requires a multidisciplinary approach, involving basic science, during the preformulation stage followed by applied science during the development stage.

This chapter will discuss the physical-chemical evaluation that takes place during the preformulation stage of development. In addition, consideration will be given to some specialized formulation ingredients that may require discretion in their selection.

Preformulation may be described as a stage of development during which the physical pharmacist characterizes the physical-chemical properties of the drug substance in question which are considered important in the formulation of a stable, effective and safe dosage form. Such parameters as crystal size and shape, pH-solubility profile, pH-stability profile, polymorphism, partitioning effect, drug permeability and dissolution behavior are evaluated. During this evaluation possible interactions with various inert ingredients intended for use in the final dosage form also are considered. The data obtained from this evaluation are integrated with data obtained from the preliminary pharmacologic and biochemical studies and provide the formulating pharmacist with information that permits selection of the optimum dosage form containing the most desirable inert ingredients for use in its development.




Fig 75-1. The wheels of product development.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.